There is no licensed vaccine or therapeutics specific to Ebola virus(EBOV) currently. The outbreak strike of Ebola virus disease (EVD) in west Africa in 2014 has brought an urgent need for the study on precautions of EVD. Small molecule inhibitors of EBOV have recently become attractive, with some of them being applied in pre-clinical trial stage. Small molecule compounds are usually designed for some mechanism of the viral pathogenesis that may be shared among different viruses, and thus display an interesting broad-spectrum of anti-viral effect. The present review would summarize the research progress on EBOV small molecule inhibitors, which block some process of the viral life cycle such as viral entry, replication and budding.